Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1986-12-5
|
pubmed:abstractText |
Forty-four adult patients with lymphoblastic lymphoma (LBL) were treated according to one of two protocols. Both included (1) induction with cyclophosphamide, doxorubicin, vincristine, prednisone, and L-asparaginase; (2) CNS prophylaxis; and (3) maintenance therapy with methotrexate (MTX) and 6-mercaptopurine. In the second protocol, CNS prophylaxis began earlier than in the first protocol and included cranial irradiation and intrathecal (IT) MTX rather than simultaneous high-dose systemic and IT MTX. The overall response rate was 100% (95% complete). With a 26-month median follow-up, the 1-and 3-year actuarial freedom from relapse (FFR) for the composite patient group was 70% and 56%, respectively. The incidence of CNS relapse was reduced from 31% in the first protocol to 3% in the second protocol (P = .04, Gehan). Patients can be assigned retrospectively to low (n = 19) and high (n = 25) risk prognostic groups, as indicated by a multivariate analysis of pretreatment prognostic factors. High-risk is defined by Ann Arbor stage IV disease with bone marrow or CNS involvement or initial serum lactate dehydrogenase (LDH) concentration of greater than 300 IU/L (normal, less than 200). FFR of low- and high-risk groups at 5 years are 94% and 19%, respectively (P = .0006). Low-risk patients are highly curable using this approach to adult LBL. More intensive treatment for high-risk patients is warranted.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0732-183X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1628-37
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3772416-Adult,
pubmed-meshheading:3772416-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3772416-Brain Neoplasms,
pubmed-meshheading:3772416-Drug Administration Schedule,
pubmed-meshheading:3772416-Female,
pubmed-meshheading:3772416-Humans,
pubmed-meshheading:3772416-L-Lactate Dehydrogenase,
pubmed-meshheading:3772416-Lymphoma, Non-Hodgkin,
pubmed-meshheading:3772416-Male,
pubmed-meshheading:3772416-Neoplasm Staging,
pubmed-meshheading:3772416-Phenotype,
pubmed-meshheading:3772416-Prognosis,
pubmed-meshheading:3772416-Risk,
pubmed-meshheading:3772416-Spinal Cord Diseases
|
pubmed:year |
1986
|
pubmed:articleTitle |
Treatment of lymphoblastic lymphoma in adults.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|